Drugs / IBI322
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05148442 | Dec 2021 → Jun 2023 | myeloid neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04912466 | Jul 2021 → Dec 2022 | neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04795128 | May 2021 → Aug 2023 | hematopoietic and lymphoid cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04338659 | Jan 2021 → Feb 2023 | lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04328831 | Jul 2020 → Aug 2023 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05296603 | Dec 2021 → Oct 2024 | small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-11 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022 innoventbio.com ↗
Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase I study for IBI322 (anti-CD47 /PD-L1 bispecific antibody) in patients with advanced solid tumors were presented today at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Poster No. CT513). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-11 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022 innoventbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI322 | “IBI322 is based on the "3+3" model, with a dose ascent starting from 10mg” NCT05296603 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-human CD47/PD-L1 bispecific antibody injection” NCT04795128 ↗ |
| Target | CD47 | “anti-human CD47/PD-L1 bispecific antibody” NCT04328831 ↗ |